Previous 10 | Next 10 |
Foamix ( FOMX ) is an Israeli biotech company that has a number of dermatological products in various stages of clinical trials and one already FDA-approved and about to launch (January 2020). It is merging with Menlo ( MNLO ), which has another interesting product currently in Phase II clin...
REDWOOD CITY, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive officer of Menlo Therapeut...
Merger activity increased with seven new deals announced and two deals closing. Deal Statistics New Deals The acquisition of Carbonite (CARB) by Open Text Corporation (OTEX) for $1.42 billion or $23.00 per share in cash. We added CARB as a potential deal to the Deals in the Work...
Shares of Foamix Pharmaceuticals (NASDAQ: FOMX) stock crashed in early trading Monday after the Israeli dermatological treatment company announced an agreement to acquire the competing, revenue-less pharmaceutical products business Menlo Therapeutics (NASDAQ: MNLO) in an all-stock tran...
Foamix Pharmaceuticals (NASDAQ: FOMX ) and Menlo Therapeutics (NASDAQ: MNLO ) have signed a definitive merger agreement to create a combined biopharmaceutical company focused on the commercialization and development of therapeutics to serve patients in the dermatology space. More news on...
Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets Menlo’s serlopitant for pruritus associated with prurigo nodularis (“PN”) complements Foamix’s existing portfolio and addresses...
Therapeutic Void Pruritus (i.e. intense itch) is a symptomatic event of chronic skin and liver diseases that is problematic for most patients. Some patients with chronic liver disease describe pruritus as feeling like something crawling under the skin, having an involuntary reaction to s...
Menlo Therapeutics (NASDAQ: MNLO ): Q3 GAAP EPS of -$0.70 beats by $0.09 . More news on: Menlo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
REDWOOD CITY, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the third quarter ended September 30, ...
- Pivotal results expected in March/April 2020 - - Details of the program to be reviewed at company’s Investor Day today in NY - REDWOOD CITY, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today anno...
News, Short Squeeze, Breakout and More Instantly...
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22 nd Annual Global Investment Confe...
BRIDGEWATER, N.J. , Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "...
Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”...